News for Vanda Pharmaceuticals Inc. (VNDA)

On March 6, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company. Following t

On February 28, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company, accordi

On February 27, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc (VNDA), purchased 10,000 shares of the company.

**media[552860]**

On February 26, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company. Followi

On February 25, 2025, Mihael Polymeropoulos, President and Chief Executive Officer of Vanda Pharmaceuticals Inc, purchased 10,000 shares of the company, accordi

PR NewswireWASHINGTON, Feb. 24, 2025 WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the public

Operator: Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals Inc. Earnings Conference Call.

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ETCompany ParticipantsKevin Moran - SVP, CFO &...

Vanda (VNDA) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals (VNDA) reports Q4 GAAP EPS of -$0.08, beating estimates by $0.06, with revenue up 17.5% Y/Y.

On January 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant transaction involving Vanda Pharmaceuticals Inc. The firm reduced its holdings b

PR NewswireWASHINGTON and SAN DIEGO, Feb. 3, 2025 Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda

PR NewswireWASHINGTON, Jan. 27, 2025 Highlights faulty FDA reviewWASHINGTON, Jan. 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA

Vanda (VNDA) has written a letter to FDA Commissioner Robert Califf asserting that the review of the market application for its drug tradipitant was flawed. Read more here.

Here, we discuss some reasons why investing in the VNDA stock now may turn out to be a prudent move.

Investing in Vanda Pharmaceuticals could prove profitable with their sales team expansion and potential revenue growth in FY 2024 results. Click here to read.

PR NewswireWASHINGTON, Dec. 20, 2024 WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. F